知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.01 seconds)

    Murine expression of human IgA Lambda locus
    3.
    发明申请
    Murine expression of human IgA Lambda locus 审中-公开
    人IgA Lambda基因座的鼠表达

    公开(公告)号：US20040231012A1

    公开(公告)日：2004-11-18

    申请号：US10753554

    申请日：2004-01-09

    Applicant: The Babraham Institute

    Inventor： Marianne Bruggemann

    IPC: A01K067/027

    CPC classification number: C12N15/8509 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0381 ,  C07K16/00 ,  C07K2317/24

    Abstract: In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of light chains are of Kappa type. The present invention discloses, among other things, transgenic mice carrying most of the human Ig Lambda light chain locus in their genome. The resulting mice express light chains with Kappa/Lambda ratio similar to the human ratio. Breeding of HuIg Lamda mice to Kappa-deficient mice also is described, as well as the generation of human monoclonal antibodies from transgenic mice with human Ig Lambda locus.

    Abstract translation: 在人类中，约60％的表达免疫球蛋白轻链是Kappa型和40％的Lambda型。 在小鼠中，几乎没有来自Lambda基因座的表达，超过95％的轻链是Kappa型的。 本发明尤其公开了在其基因组中携带大部分人Ig Lambda轻链基因座的转基因小鼠。 所得到的小鼠以Kappa /λ比率表示与人的比例相似的轻链。 还描述了将HuIg Lamda小鼠育种到Kappa缺陷小鼠，以及用具有人Ig Lambda基因座的转基因小鼠产生人单克隆抗体。

    MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY
    6.
    发明申请
    MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY 审中-公开
    MIR-155增强CD8 + T细胞免疫

    公开(公告)号：US20140120136A1

    公开(公告)日：2014-05-01

    申请号：US14051895

    申请日：2013-10-11

    Applicant: The Babraham Institute ,  Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine

    Inventor： Peter D. Katsikis ,  Donald T. Gracias ,  Martin Turner

    IPC: C12N15/113

    CPC classification number: C12N15/113 ,  A61K35/17 ,  C12N5/0636 ,  C12N2310/141 ,  C12N2501/65

    Abstract: The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as “CD8+ T cell immunity”) in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells.

    Abstract translation: 本发明提供了具有疾病状态的患者中增强CD8 + T细胞介导的免疫（也称为“CD8 + T细胞免疫”）的新方法。 特别地，本发明通过引入编码miR-155转录物的核酸分子或编码嵌合抗原受体和miR的核酸分子来提供miR-155在患者特异性T细胞群体中的增强表达 -155转录到这些细胞中，随后将T细胞重新引入患者体内。 本发明还提供了相对于对照细胞增强这些T细胞的扩增的方法。 增强的miR-155表达后CD8 + T细胞的增加与增强的CD8 + T细胞免疫直接相关。 本发明还提供了通过增加miR-155在患者特异性T细胞中的表达来增强患者抗癌免疫的方法。

    NOVEL METHOD
    7.
    发明申请
    NOVEL METHOD 有权

    公开(公告)号：US20220220180A1

    公开(公告)日：2022-07-14

    申请号：US17653554

    申请日：2022-03-04

    Applicant: Babraham Institute ,  VIB VZW ,  Katholieke Universiteit Leuven, K.U. Leuven R&D

    Inventor： Matthew HOLT ,  Adrian LISTON ,  James DOOLEY

    IPC: C07K14/55 ,  A61K35/17 ,  C12N15/86

    Abstract: The invention relates to a method of expanding a population of regulatory T cells in a tissue or organ of a subject, wherein said method comprises administration of IL-2 and a targeting moiety specific for said tissue or organ, and wherein said tissue or organ is the central and/or peripheral nervous system. The invention further relates to populations of regulatory T cells produced according to the method and the production of said population in vivo. Also provided is a pharmaceutical composition comprising IL-2 and a targeting moiety as defined herein as well as a method of treating a disease or disorder mediated by inflammation or for the reduction of inflammation which comprises the methods defined herein or administration of a pharmaceutical composition as defined herein.

    NOVEL REPROGRAMMING METHOD
    8.
    发明申请
    NOVEL REPROGRAMMING METHOD 有权

    公开(公告)号：US20220112468A1

    公开(公告)日：2022-04-14

    申请号：US17555793

    申请日：2021-12-20

    Applicant: Babraham Institute

    Inventor： Wolf REIK ,  Diljeet GILL ,  Thomas STUBBS

    IPC: C12N5/074 ,  C12N15/86 ,  C12N15/90 ,  C12Q1/6883 ,  G01N33/50 ,  C12Q1/6809 ,  A61K35/545 ,  A61K8/98 ,  A61Q19/08

    Abstract: The invention relates to methods of reprogramming a somatic cell comprising culturing the somatic cell in the presence of one or more Yamanaka factors and further culturing said somatic cell in the absence of said one or more Yamanaka factors. The invention further relates to a reprogrammed somatic cell produced according to the methods as defined herein. Also provided are cosmetic methods, cosmetic compositions, a reprogrammed somatic cell and compositions for use in treatment or rejuvenation, as well as methods for screening age modulating agents, factors and/or cellular processes, comprising the methods and a reprogrammed somatic cell as defined herein.

    Derivation of pluripotential embryonic cell lines from domestic animals
    10.
    发明申请
    Derivation of pluripotential embryonic cell lines from domestic animals 审中-公开
    衍生家养动物的多能胚胎细胞系

    公开(公告)号：US20020187549A1

    公开(公告)日：2002-12-12

    申请号：US10175277

    申请日：2002-06-20

    Applicant: Babraham Institute

    Inventor： Martin John Evans ,  Robert Michael Moor ,  Elena Notaranni

    IPC: C12N005/06 ,  A01K067/027

    CPC classification number: C12N5/0603 ,  C12N5/0606

    Abstract: A method of selecting and growing pluripotential embryonic stem cells isolated from an ungulate species blastocysts of embryos that develop by way of an embryonic disc is disclosed. The method comprises growing blastocysts in tissue culture growth medium which includes both heat-inactivated new born calf serum and heat-inactivated fetal calf serum; disaggregating the blastocysts either after spontaneous hatching or after mechanical removal of the zone pellucida; growing stem cell colonies from the disaggregated cells in issue culture growth medium; selecting stem cell colonies by morphological characteristics; and growing the selected stem cells in tissue culture growth medium. The cells are round cells, tightly packed with large nuclei in relation to cytoplasm, and fairly prominent nucleoli. They grow in tightly adherent coloedes and as the colonies get larger the cells tend to flatten out in the center of the colony. The outer, less flattened cells of a larger colony or all the cells of a smaller colony without central flattening are readily disaggregated by trypsinization into small spherical cells which have a bright phase contrast appearance, and if observed after a short time of incubation at 37 C. they show lobular pseudopodia

    Abstract translation: 公开了一种选择和生长通过胚胎盘形成的有蹄类动物胚胎胚泡分离的多潜能胚胎干细胞的方法。 该方法包括在组织培养生长培养基中培养囊胚，其包括热灭活的新生小牛血清和热灭活的胎牛血清; 在自发孵化后或在机械去除透明带之后分解囊胚; 在问题培养生长培养基中分解的细胞培养干细胞集落; 通过形态特征选择干细胞集落; 并在组织培养生长培养基中生长选定的干细胞。 细胞是圆形细胞，紧密地填充有与细胞质相关的大核，以及相当突出的核仁。 它们生长在紧密粘连的细胞中，随着菌落越来越细，细胞倾向于在殖民地的中心变平。 更大菌落的外部，较小的扁平细胞或没有中心平坦化的较小菌落的所有细胞通过胰蛋白酶解容易分解成具有明亮相位对比度外观的小球形细胞，并且如果在37℃下孵育短时间后观察到 他们显示小叶伪足

Patent Agency Ranking